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Abstract
Backgrounds: Durability of androgen-deprivation therapy (ADT) for prostate cancer (PC) is limited. Additional
selective estrogen receptor modulators (SERMs) may prolong the durability of ADT, because androgen and
estrogen signaling drive PC progression.
Methods: Men with treatment-naïve bone metastatic PC were randomly assigned in 1:1:1 fashion to receive ADT,
toremifene 60 mg plus ADT (TOPADT), or raloxifene 60 mg plus ADT (RAPADT). The primary endpoint was the
biochemical recurrence (BCR) rate, and secondary endpoints were changes of scores of the visual analogue scale
(VAS) and the functional assessment of cancer therapy (FACT).
Results: A total of 15 men, 5 each, were allocated to one of the three treatment arms. The basal serum prostate-
specific antigen (PSA) level was 198 ng/mL (median, range; 30–8428). Bone metastases were graded as 1 (n = 11), 2
(n = 3), and 3 (n = 1) by the extent of disease. During the median follow-up period of 1370 days (range; 431–1983),
BCR occurred in 3, 0 and 2 men in ADT, TOPADT and RAPADT group, respectively. The 5-year BCR-free rate was 30,
100 and 53 %, in ADT, TOPADT and RAPADT group, respectively (p = 0.04, ADT v.s. TOPADT, p = 0.48, ADT v.s. RAPADT
and p = 0.12, TOPADT v.s. RAPADT). Scores of VAS improved in all groups and remained stable throughout the study.
This analysis is limited as a preliminary result in a single center.
Conclusions: Toremifene with conventional ADT significantly improved the BCR rate in treatment-naïve bone
metastatic PC. Further clinical trials are warranted to confirm the promising clinical efficacy of this combination therapy.
Trial registration: The protocol was registered at the University Hospital Medical Information Network (UMIN
ID;0,000,064,000) in Sep 25, 2011.
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Background
Based on the pioneering work by Huggins [1], androgen
deprivation therapy (ADT) has been the primary treat-
ment for advanced prostate cancer (PC). Unfortunately,
most advanced cases of PC eventually become castration-
resistant (CRPC), despite the continued use of ADT [2].
Novel therapies such as docetaxel, enzaltamide, abirater-
one, cabazitaxel and sipuleucel-T [2–5] have been devel-
oped to treat CRPC. However, the development of agents
that inhibit progression to CRPC may represent alterna-
tive therapeutic options for PC.
The results of recent studies have revealed growth
regulation of PC via steroid nuclear receptors, which in-
cluded not only the androgen receptor (AR) [6, 7] but
also members of the estrogen receptor (ER) family [8, 9].
ERα and ERβcx (ERβ2) in particular have been impli-
cated in PC progression and PC-related mortality,
whereas ERβ inhibits tumor growth [8, 9]. In this re-
gard, selective estrogen receptor modulators (SERMs)
are expected to change the clinical course of PC. For
example, toremifene, an ERα antagonist in the prostate
[10], decreased the incidence of PC in men with high-
grade prostatic intraepithelial neoplasia (HGPIN) [11, 12].
Furthermoere, raloxifene inhibited androgen-independent
PC growth in 5 (28 %) of 13 patients [13]. However,
SERMs have not been fully investigated for use in those
with treatment-naïve PC. We hypothesized that additional
SERMs may prolong the durability of ADT, because an-
drogen and estrogen signaling drive PC progression. In
the present study, we conducted a prospective random-
ized clinical phase IIA trial to investigate the effects of
SERMs (toremifene and raloxifene) when added to ADT
in treatment-naïve bone metastatic PC.
Methods
Participants
The inclusion criteria were men aged ≥20 years if they
had histological confirmed adenocarcinoma of the pros-
tate and radiologically proven bone metastasis with per-
formance status 0, and adequate hepatic, hematological
and renal function. Patients who had previous ADT or
chemotherapy for PC, deep vein thrombosis, pulmonary
embolism or antiphospholipid antibody syndrome were
excluded. Bisphosphonate, warfarin, phenobarbital, ri-
fampicin, phenitoin, ampicillin or cholestyramine was
not allowed during the study.
Extent of diseases (EOD) of bone metastasis was graded
by bone scintigraphy using technetium-99 m-methylene
diphosphonate as follows: 0, normal or abnormal due to
benign bone disease; 1, number of bony metastases <6,
each of which was <50 % of the size of a vertebral body
(one lesion approximately the size of a vertebral body
would be counted as two lesions); 2, number of bone me-
tastases between 6 and 20, size of lesions as previously
described; 3, number of metastases ≥20 but less than a
“super scan”, and 4, “super scan” or its equivalent, i.e.,
more than 75 % of the ribs, vertebrae and pelvic bones
[14]. The Japan Cancer of the Prostate Risk Assessment
(J-CAPRA) score (range; 0–12) was calculated on the
basis of GS, PSA levels and clinical stage [15].
The protocol was approved by the ethical committee
(Internal Review Board) at the University of Tokyo
Hospital in August 2008 (approval number; P2008054)
entitled preliminary study of selective estrogen modula-
tors (SERMs) combined with maximum androgen block-
ade for metastatic prostate cancer (see Additional file 1:
Table S1). And the study was also registered at the
University Hospital Medical Information Network (UMIN
ID; 0000064000). All patients provided written informed
consent. An analysis was performed and reported to the
Internal Review Board in the University of Tokyo Hospital
every year.
Study design
Figure 1 shows the consolidated standards of reporting
trials (CONSORT) flow diagram of recruited patients
and follow-up. Eligible patients were randomly allocated
in a 1:1:1 fashion to receive ADT alone, toremifene plus
Fig. 1 CONSORT flow diagram of recruited patients and follow-up.
Men diagnosed with PC by trans-rectal prostate needle biopsy
underwent a bone scan. If patients had bone metastasis and agreed
to participate in the trial, they were assigned to receive ADT alone,
TOPADT or RAPADT in a 1:1:1 ratio (n = 15)
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ADT (TOPADT) or raloxifene plus ADT (RAPADT).
ADT consisted of castration [bilateral orchiectomy or
luteinizing hormone-releasing hormone (LHRH) ago-
nists] combined with 80 mg of bicalutamide. The LHRH
agonist was administered throughout, whereas bicaluta-
mide was changed to flutamide on biochemical recur-
rence after denying anti-androgen withdrawal syndrome.
Toremifene (Orion Corporation, Finland) and raloxifene
(Eli Lilly Japan K.K.) were given at a dose of 60 mg orally
every day combined with aspirin 100 mg daily for
prophylactic anti-coagulation.
After PC became hormone-refractory, administration
of flutamide was switched to systemic chemotherapy
which was performed every 3–4 weeks. If PC became
both hormone refractory and chemotherapy-refractory,
patients received best supportive care.
Study end points
Patients were monitored every month during the first
year, and every 3 months thereafter. The primary end-
point was the BCR, which was defined as consecutive in-
crease in serum PSA levels to above the patient’s PSA
nadir [16]. Secondary endpoints included pain on a vis-
ual analogue scale (VAS) and functional assessment of
cancer therapy (FACT) in every 3 months [17].
Immunohistochemical analysis
The immunohistochemical analyses for AR, ERα and
ERβ were performed using the streptavidin-biotin amplifi-
cation method and an EnVision + visualization kit (Dako,
Carpinteria, CA, USA) as previously described [9]. The
primary antibody against AR (1:40 dilution), ERα (1:40 di-
lution) and ERβ (1:200 dilution) was applied and incu-
bated at room temperature for 1 h. The sections were
then rinsed in phosphate-bufferes saline and incubated at
room temperature with EnVision + for 1 h. The antigen-
antibody complex was visualized with 3, 3′-diaminobenzi-
dine (DAB) solution [1 mM DAB, 50 mM Tris–HCl buffer
(pH 7.69, and 0.006 % H2O2]. The monoclonal antibodies
for AR (AR441) and ERα (NCL-ER-6 F11) were pur-
chased from Dako (Dako, Carpinteria, CA, USA) and
Novo-castra Laboratories (Newcastle upon Tyne, UK),
respectively. A polyclonal antibody specific for ERβ was
raised in rabbits against peptides synthesized to corres-
pond to the C-terminal region of ERβ (CSPAEDSKS
KEGSQNPQSQ) [9].
Immunohistochemical assessment
The labeling index (LI) was determined by counting the
percentage of cells with positive immunoreactivity per
1000 cells [18]. Two trained pathologists (TF and YY)
independently evaluated the tissue sections, and the
average LI was used. We defined positive immunoreac-
tivity as showing moderate or strong immunoreactivity.
Statistical analyses
Correlations between age, pretreatment serum PSA
levels, J-CAPRA score [15], and LI were evaluated using
the Wilcoxon rank sum test. Associations between the
group and clinical parameters including Gleason score
(GS) and clinical stage were assessed using chi-square
tests. BCR-free survival curves were plotted using the
Kaplan-Meier method and verified using the log-rank
test and univariate Cox proportional hazards regression
models. JMP 11.0.0 software (SAS Institute, Cary, NC,
USA) was used for all statistical analyses, and p < 0.05
was considered to indicate statistical significance.
Results
Patient characteristics
From August 14, 2008 to December 27, 2012, 15 pa-
tients were enrolled and randomly allocated to either of
the three treatment groups as shown in Table 1. The
median age was 74 years (range, 63–85). Pretreatment
serum PSA levels were 30–8428 ng/mL (median, 198 ng/
mL). The biopsy samples were evaluated by two patholo-
gists as GS 7 (n = 3), 8 (n = 5), 9 (n = 5), or 10 (n = 2). The
median J-CAPRA score was 9 (range, 6–11). There was
no statistically significant difference in age, serum PSA
level, stage, GS, EOD, J-CAPRA score or LI against the
anti-AR, −ERα, and-ERβ antibodies among the three
groups [ADT v.s. TOPADT and ADT v.s. RAPADT;
Fig. 2].
Primary endpoint
Table 2 shows the PSA response and outcome after
ADT with or without SERMs. One patient discontinued
toremifene becauseof a headache during the median
follow-up period of 1370 days (range, 431–1983). Five
(33 %) (2, 2, 1 in the three groups, respectively) patients
achieved a PSA-nadir ≤0.01. At the end of the follow-up
period, 5 (33 %) patients (3 in the ADT group and 2 in
the RAPADT group) experienced BCR and were
switched from bicaltamide to flutamide. One patient in
the ADT group became hormone-refractory rapidly and
died of PC on day 431 without chemotherapy. One pa-
tient in the TOPADT group died of gastric cancer with-
out showing BCR on day 1371. The BCR-free survival
rate was significantly higher in men treated with
TOPADT than in those received ADT only (p = 0.04,
ADT vs. TOPADT; p = 0.48, ADT vs. RAPADT;, and p =
0.12, TOPADT vs. RAPADT; Fig. 3).
Table 3 shows the results obtained from univariate
Cox proportional hazards regression models for BCR as-
sociated with treatment and the clinicopathological char-
acteristics of the patients, including age, serum PSA
levels, J-CAPRA score and LI of AR, ERα and ERβ.
TOPADT was only found to be significant in the univar-
iate analysis (p = 0.023; hazard ratio, 1.1 e−9).
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Table 1 Baseline characteristics (n = 15)
ADT (n = 5) TOPADT (n = 5) P value (vs. ADT) RAPADT (n = 5) P value (vs. ADT)
Age (median, range) 76 (74–85) 73 (63–81) 0.59 72 (67–75) 0.29
PSA (ng/mL) (median, range) 223 (30.6–8428) 264 (30–818) 1 126 (30.8–3600) 0.83
Gleason score 7 1 0 0.72 2 0.57
8 2 2 1
9 1 2 2
10 1 1 0
Clinical T stage 2c 2 4 0.19 2 0.55
3a 3 1 2
3b 0 0 0
4 0 0 1
Clinical N stage 0 2 4 0.19 1 1
1 3 1 4
Clinical M stage 1b 5 4 1 5 1
1c 0 1: lung 0
Extent of disease 1 4 3 0.49 4 1
2 0 2 1
3 1 0 0
J-CAPRA score (median, range) 9 (8–10) 8 (7–9) 0.37 9 (6–11) 0.92
Labeling index (median, range)
AR 78.5 (54.8–100) 87.1 (30–100) 1 100 (37.5–100) 0.68
ERα 27.9 (0–46.5) 19.7 (0–37.4) 0.34 20.6 (13.4–35.4) 0.54
ERβ 20.3 (2.4–44.9) 11.9 (7.4–91.4) 0.75 15.2 (7–26.4) 0.9
ADT androgen deprivation therapy including surgical or medical castration plus bicalutamide, TOPADT toremifene plus ADT, RAPADT raloxifene plus ADT, J-CAPRA
score Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score (ranging from 0 to 12) was calculated on the basis of PSA, Gleason score and clinical stage
[15]. Labeling index was determined by counting the percentage of cells with positive immunoreactivity in 1000 cells [18], AR androgen receptor, ER
estrogen receptor
Fig. 2 Immunohistochemical staining for AR (a), ERα (b) and ERβ (c) in the tissue sections from the same area of a patient with PC. Strong (a) or
moderate (b and c) staining was identified in the nuclei of cancer cells. The LI of AR (a), ERα (b) and ERβ (c) in cancer cells was 100, 35.4 and
26.4, respectively. Scale bar =100 μm
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Hot flush was observed in all groups; ADT (n = 2),
TOPADT (n = 3), and RAPADT (n = 3); although, all pa-
tients continued on therapy.
Secondary endpoint
The VAS scores were significantly decreased after treat-
ment (p = 0.04, pre-treatment vs. 3 months thereafter),
and showed no statistical differences among the three
groups (Fig. 4a). Scores of physical well-being, social
well-being, emotional well-being, functional well-being,
as well as PC subscale scores of FACT questionnaire,
were stable during the follow-up period and not statisti-
cally different among the three groups (Fig. 4b–f ).
Discussion
The most common initial therapy for metastatic PC is
ADT; however, the durability of ADT is limited and af-
fected by various factors including pretreatment PSA
level, GS, tumor stage and PSA nadir [19]. The durabil-
ity of ADT is also influenced by the ER status of the
tumor [18, 20].
In fact, estrogens were initially used as one of the
earliest forms of treatment agents; however, they were
associated with thromboembolic and cardiovascular side
effects [21]. SERMs are synthetic estrogen ligands that
can exhibit either estrogenic or anti-estrogenic effects
depending on tissue types [22]. Toremifene significantly
reduced the incidence of PC in a transgenic adenocar-
cinoma mouse prostate model [23], as well as in men
with HGPIN [11]. In addition, toremifene increased the
bone mineral density of the hip and spine [24] and im-
proved lipid profiles in men receiving ADT for PC [25].
Raloxifene, which acts as an ER agonist in the bone tis-
sue [26], has been developed for the treatment of osteo-
porosis in women [27] and showed some tumor-inhibitory
effects in CRPC in a pilot study [13]. To date, the anti-
cancer effects of these SERMs have not yet been fully
investigated in treatment-naïve PC patients. We hy-
pothesized that concurrent use of SERMs would pro-
long the duration of efficacy of ADT in men with bone
metastatic PC.
Currently, we have demonstrated that TOPADT sig-
nificantly improved the biochemical recurrence rate in
men with bone metastatic PC compared with men
treated with ADT alone. The results of a recent study
Table 2 PSA response and outcome after ADT with or without selective estrogen receptor modulators (n = 15)
ADT (n = 5) TOPADT (n = 5) RAPADT (n = 5)
Follow-up period (median, range) 1169 (431―1631) 1653 (730―1983) 1570 (750―1883)
PSA nadir (ng/mL) ≥1 1 0 1
0.01–1.0 2 3 3
≤0.01 2 2 1
Biochemical recurrence No 2 5 3
Yes 3 0 2
Outcome Alive with disease 4 4 5
Died of PC 1 0 0
Died of other disease 0 1: Died of gastric cancer 0
Adverse event Hot flush: 2 Hot flush: 3, Headache: 1 Hot flush: 3
ADT androgen deprivation therapy including surgical or medical castration plus bicalutamide, TOPADT toremifene plus ADT, RAPADT raloxifene plus ADT, PC
prostate cancer
Fig. 3 PSA relapse-free survival rates in men with TOPADT, RAPADT
and ADT alone (n = 15). The PSA relapse-free survival rate in men
treated with TOPADT was significantly greater than in men treated
with ADT alone (p = 0.04)
Table 3 Univariate Cox proportional hazard regression models
of biochemical recurrence free survival (n = 15)
Univariate
Variable Hazard ratio 95 % index p value
Age (≥74 vs. <74) 3.9 0.57–75 0.18
Serum PSA (ng/mL) (≥198 vs. <198) 1.9 0.33–15 0.45
J-CAPRA (≥9 vs. ≤8) 1.7 0.27–12 0.57
AR LI (≥93.5 vs. <93.5) 1.2 0.19–8.7 0.87
ERα LI (≥23.2 vs. <23.2) 0.40 0.05–2.5 0.32
ERβ LI (≥16.1 vs. <16.1) 0.73 0.09–4.4 0.73
TOPADT vs. MAB 1.1 e−9 0.64–0.64 0.023
RAPADT vs. MAB 0.5 0.069–3.2 0.48
Fujimura et al. BMC Cancer  (2015) 15:836 Page 5 of 8
showed that the 5-year BCR-free rate was 30 % in men
who received ADT plus docetaxel with median serum
PSA levels of 26.7 (range, 5.0–106) [5]. In our study,
similar rates were noted for men treated with ADT alone
(30 %). Surprisingly, the 5-year BCR-free rate in the
TOPADT group was 100 %.
Theoretically, the tumor inhibitory effects of toremi-
fene would be mediated via the suppression of ERα-
related signals [28, 10]. ERα expression in PC cells was
confirmed by immunohistochemistry and quantitative
reverse transcription polymerase chain reaction analyses
[8, 9, 18]. The mRNA expression of ERα was much
lower than AR in PC cells (1:100 ratio); however, ERα
expression in cancer-associated stromal cells was signifi-
cantly related to cancer-specific survival in men with
bone metastatic PC [18]. ERα expression was negatively
correlated with survival after radical prostatectomy in lo-
cally advanced PC [29]. Additionally, ERα promoted pro-
liferation by regulating MYC expression and glucose
sensitivity in phosphatase and tensin homolog (PTEN)-
deficient mouse PC cells [8]. Conversely, depletion of
ERα inhibited growth in PTEN-deficient mice via a re-
duction in MYC protein and alteration of glucose
sensitivity [8]. The results of present study demonstrated
that toremifene significantly improved the durability of
ADT, suggesting blockade of ERα signaling as a potential
target for advanced PC.
ERβ signaling has been associated with a tumor-
inhibitory effect in PC through both the classical (ERβ
and estrogen-response element complex) and non-
classical pathways (ERβ, Krüppel-like zinc finger tran-
scription factor 5, and adenosine 3′,5′-monophosphate
response element-binding protein-binding protein com-
plex) [30]. ERβ modulators are expected to inhibit PC
growth. Raloxifene exhibits diverse activities via ER de-
pending on whether ERα or ERβ is expressed in the tar-
get organ [26]. The results of the present study did not
prove a distinct tumor-inhibitory effect mediated by
RAPADT as compared to ADT alone. The difference in
the reason tumor inhibitory effect between TOPADT
and RAPADT may have been attributed to the potency
of the drugs and the pattern of ER expression in PC
cells. The tumor-inhibitory effect of fulvestrant, another
ERβ modulator, was limited because the median time to
progression was only 4.3 months in men with CRPC
treated with fulvestrant [31]. Further investigations of
Fig. 4 The change in VAS scores following treatment for PC (a). The VAS scores were significantly decreased after the treatment (p = 0.04, pre
treatment vs. 3, 6, 9 and 12 months of treatment). Statistically significant differences were not detected among the three groups. The FACT of
before treatment and after 3, 6, 9 and 12 months of treatment. Physical well-being (PWB; b), social well-being (SWB; c), emotional well-being
(EWB; d), functional well-being (FWB; e) and prostate cancer (PC) scale scores (f) were stable during the follow-up period. Statistically significant
differences were not detected among the three groups in PWB (p = 0.5, pre treatment v.s. 3, 6, 9 and 12 months of treatment), SWB (p = 0.5,
pretreatment vs. 3, 6, 9 and 12 months of treatment), EWB (p = 0.75, pre treatment v.s. 3, 6, 9 and 12 months of treatment), FWB (p = 0. 5, pretreatment
vs. 3, 6, 9 and 12 months of treatment), and PC sub scale (p = 0.25, pretreatment v.s. 3, 6, 9 and 12 months of treatment)
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additional ERβ modulators are warranted with respect to
their potential role in the inhibition of human PC.
The known adverse events associated with the use of
SERMs include hot flushes, sweating, nausea, dizziness,
edema, vomiting and thrombosis [27]. In the present
study, two men in the ADT group, two men in the
TOPADT group, and three men in the RAPADT group
complained of mild hot flushes; however, no medical
intervention was deemed necessary. Only one man in
the TOPADT group discontinued toremifene administra-
tion because of a headache. No events of liver dysfunc-
tion or thrombosis were observed.
The present study was not without limitations. The
sample size was small, and the cohort was limited to a
single institution in an all Asian population. A multicen-
ter external validation study would be necessary to fur-
ther elucidate the additional effect of toremifene on
ADT that we found in patients with advanced PC.
Conclusions
Results from the present study we demonstrated the
good clinical efficacy and tolerability of TOPADT in pa-
tients with treatment-naïve bone metastatic PC. Add-
itional clinical trials with larger cohorts are warranted to
confirm our promising phase IIA results.
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